611 related articles for article (PubMed ID: 19921118)
1. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
3. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
Van Wagner LB; Rinella ME
Therap Adv Gastroenterol; 2011 Jul; 4(4):249-63. PubMed ID: 21765869
[TBL] [Abstract][Full Text] [Related]
4. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
[TBL] [Abstract][Full Text] [Related]
5. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
6. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
Le TA; Loomba R
J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Lomonaco R; Sunny NE; Bril F; Cusi K
Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
[TBL] [Abstract][Full Text] [Related]
9. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
10. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
11. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
12. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
Farrell GC; Larter CZ
Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Nonalcoholic Fatty Liver Disease.
Liangpunsakul S; Chalasani N
Curr Treat Options Gastroenterol; 2003 Dec; 6(6):455-463. PubMed ID: 14585234
[TBL] [Abstract][Full Text] [Related]
17. The treatment of NAFLD.
Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging therapies in nonalcoholic fatty liver disease.
Kashi MR; Torres DM; Harrison SA
Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacological treatment of nonalcoholic fatty liver.
Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
Curr Med Chem; 2006; 13(24):2889-900. PubMed ID: 17073635
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
